Does aspirin use make it harder to collect seizures during elective video-EEG telemetry?

Godfred, Rachel; Parikh, Mihir; Haltiner, Alan M.; Caylor, Lisa; Sepkuty, Jehuda P.; Doherty, Michael

doi:10.1016/j.yebeh.2012.12.031

Cited by 22 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings were further validated by Lance et al who observed seizure control in 91% of the patients with the syndrome receiving low-dose aspirin with minimal side effects [162]. Patients with focal epilepsy receiving aspirin also showed significantly fewer seizures compared to age-, sex- and disease-matched controls not receiving aspirin [163]. They found an inverse correlation between aspirin doses and seizure frequency.…”

Section: Introductionmentioning

confidence: 59%

Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management

Rawat

Kukal

Dahiya

et al. 2019

J Neuroinflammation

113

View full text Add to dashboard Cite

Epilepsy, a common multifactorial neurological disease, affects about 69 million people worldwide constituting nearly 1% of the world population. Despite decades of extensive research on understanding its underlying mechanism and developing the pharmacological treatment, very little is known about the biological alterations leading to epileptogenesis. Due to this gap, the currently available antiepileptic drug therapy is symptomatic in nature and is ineffective in 30% of the cases. Mounting evidences revealed the pathophysiological role of neuroinflammation in epilepsy which has shifted the focus of epilepsy researchers towards the development of neuroinflammation-targeted therapeutics for epilepsy management. Markedly increased expression of key inflammatory mediators in the brain and blood-brain barrier may affect neuronal function and excitability and thus may increase seizure susceptibility in preclinical and clinical settings. Cyclooxygenase-2 (COX-2), an enzyme synthesizing the proinflammatory mediators, prostaglandins, has widely been reported to be induced during seizures and is considered to be a potential neurotherapeutic target for epilepsy management. However, the efficacy of such therapy involving COX-2 inhibition depends on various factors viz., therapeutic dose, time of administration, treatment duration, and selectivity of COX-2 inhibitors. This article reviews the preclinical and clinical evidences supporting the role of COX-2 in seizure-associated neuroinflammation in epilepsy and the potential clinical use of COX-2 inhibitors as a future strategy for epilepsy treatment.

show abstract

Section: Introductionmentioning

confidence: 59%

Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management

Rawat

Kukal

Dahiya

et al. 2019

J Neuroinflammation

113

View full text Add to dashboard Cite

show abstract

“…A preliminary clinical study also showed decreased seizure frequency for epilepsy patients on day 2 after starting to take aspirin. The authors of this study emphasize that further prospective study is needed towards this direction (Godfred et al, 2013 ). Thus, the usage of aspirin (and possibly other antiplatelet drugs) is a perspective for the prevention and treatment of epilepsy.…”

Section: Platelets As Targets For Future Therapymentioning

confidence: 90%

The Role of Platelets in the Stimulation of Neuronal Synaptic Plasticity, Electric Activity, and Oxidative Phosphorylation: Possibilities for New Therapy of Neurodegenerative Diseases

Kopeikina

Ponomarev

2021

Front. Cell. Neurosci.

View full text Add to dashboard Cite

The central nervous system (CNS) is highly vascularized where neuronal cells are located in proximity to endothelial cells, astroglial limitans, and neuronal processes constituting integrated neurovascular units. In contrast to many other organs, the CNS has a blood-brain barrier (BBB), which becomes compromised due to infection, neuroinflammation, neurodegeneration, traumatic brain injury, and other reasons. BBB disruption is presumably involved in neuronal injury during epilepsy and psychiatric disorders. Therefore, many types of neuropsychological disorders are accompanied by an increase in BBB permeability leading to direct contact of circulating blood cells in the capillaries with neuronal cells in the CNS. The second most abundant type of blood cells are platelets, which come after erythrocytes and outnumber ~100-fold circulating leukocytes. When BBB becomes compromised, platelets swiftly respond to the vascular injury and become engaged in thrombosis and hemostasis. However, more recent studies demonstrated that platelets could also enter CNS parenchyma and directly interact with neuronal cells. Within CNS, platelets become activated by recognizing major brain gangliosides on the surface of astrocytes and neurons and releasing a milieu of pro-inflammatory mediators, neurotrophic factors, and neurotransmitters. Platelet-derived factors directly stimulate neuronal electric and synaptic activity and promote the formation of new synapses and axonal regrowth near the site of damage. Despite such active involvement in response to CNS damage, the role of platelets in neurological disorders was not extensively studied, which will be the focus of this review.

show abstract

“…In a retrospective study, including 23 adults with focal onset epilepsy who took aspirin daily, whereas undergoing elective video‐EEG monitoring, less seizures were observed as compared to 23 patients that were not taking aspirin. Furthermore, higher aspirin doses were correlated with fewer seizures during the monitoring period . However, these data should be interpret with caution, as stated by the authors: ‘The associations are modest and borderline insignificant, the study remains underpowered, and the study group is narrow, tertiary and not designed to address aspirin efficacy in seizure control.…”

Section: Cox‐2 Signallingmentioning

confidence: 99%

Review: Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies

Vliet

Aronica

Vezzani

et al. 2018

Neuropathology Appl Neurobio

206

142

View full text Add to dashboard Cite

Accumulating evidence indicates an important pathophysiological role of brain inflammation in epilepsy. In this review, we will provide an update of specific inflammatory pathways that have been proposed to be crucial in the underlying molecular mechanisms of epilepsy, including the interleukin-1 receptor/toll-like receptor signalling, cyclooxygenase-2, tumour necrosis factor-alpha, complement signalling and chemokines. Furthermore, by drawing on evidence from preclinical and clinical studies we will discuss the potential of these signalling pathways targets for novel therapeutic interventions that control drug-resistant seizures or have disease-modifying effects. Finally, we will assess the use of these inflammatory pathways as potential biomarkers for the development of epilepsy or to measure the effectiveness of therapeutic interventions.

show abstract

Does aspirin use make it harder to collect seizures during elective video-EEG telemetry?

Cited by 22 publications

References 8 publications

Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management

Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management

The Role of Platelets in the Stimulation of Neuronal Synaptic Plasticity, Electric Activity, and Oxidative Phosphorylation: Possibilities for New Therapy of Neurodegenerative Diseases

Review: Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies

Contact Info

Product

Resources

About